Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Bosch

Showing results (641-650 of 681) with videos related to

Pageof 69
Sort By:
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 3, 2014
Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical diseaseElmar A Joura, Kevin A Ault, F Xavier Bosch, et al.
Clinical and Experimental Dermatology|March 2, 2024
Efficacy of omalizumab for the treatment of bullous pemphigoid: Spanish multicentre real-world experienceÁlvaro Aguado Vázquez, Andrea Estébanez Corrales, F Javier Melgosa Ramos, et al.
Ebiomedicine|July 22, 2023
Evaluation of somatic mutations in cervicovaginal samples as a non-invasive method for the detection and molecular classification of endometrial cancerBeatriz Pelegrina, Sonia Paytubi, Fátima Marin, et al.
The Lancet. Oncology|November 15, 2011
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialCosette M Wheeler, Xavier Castellsagué, Suzanne M Garland, et al.
Gynecologic Oncology|September 4, 2012
Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trialEdith Roset Bahmanyar, Jorma Paavonen, Paulo Naud, et al.
Clinical and Vaccine Immunology : CVI|February 6, 2015
Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trialDan Apter, Cosette M Wheeler, Jorma Paavonen, et al.
Journal of Clinical Medicine|October 15, 2020
Skin Manifestations in COVID-19: Prevalence and Relationship with Disease SeverityPriscila Giavedoni, Sebastián Podlipnik, Juan M Pericàs, et al.
BMC Infectious Diseases|May 1, 2015
Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trialXavier Castellsagué, Jorma Paavonen, Unnop Jaisamrarn, et al.
International Journal of Cancer|January 3, 2014
Time trends of human papillomavirus types in invasive cervical cancer, from 1940 to 2007Laia Alemany, Silvia de Sanjosé, Sara Tous, et al.
Vaccine|November 16, 2013
Comprehensive control of human papillomavirus infections and related diseasesF Xavier Bosch, Thomas R Broker, David Forman, et al.
Pageof 69

Showing results (641-650 of 681) with videos related to

Sort By:
Pageof 69
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 3, 2014
Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical diseaseElmar A Joura, Kevin A Ault, F Xavier Bosch, et al.
Clinical and Experimental Dermatology|March 2, 2024
Efficacy of omalizumab for the treatment of bullous pemphigoid: Spanish multicentre real-world experienceÁlvaro Aguado Vázquez, Andrea Estébanez Corrales, F Javier Melgosa Ramos, et al.
Ebiomedicine|July 22, 2023
Evaluation of somatic mutations in cervicovaginal samples as a non-invasive method for the detection and molecular classification of endometrial cancerBeatriz Pelegrina, Sonia Paytubi, Fátima Marin, et al.
The Lancet. Oncology|November 15, 2011
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialCosette M Wheeler, Xavier Castellsagué, Suzanne M Garland, et al.
Gynecologic Oncology|September 4, 2012
Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trialEdith Roset Bahmanyar, Jorma Paavonen, Paulo Naud, et al.
Clinical and Vaccine Immunology : CVI|February 6, 2015
Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trialDan Apter, Cosette M Wheeler, Jorma Paavonen, et al.
Journal of Clinical Medicine|October 15, 2020
Skin Manifestations in COVID-19: Prevalence and Relationship with Disease SeverityPriscila Giavedoni, Sebastián Podlipnik, Juan M Pericàs, et al.
BMC Infectious Diseases|May 1, 2015
Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trialXavier Castellsagué, Jorma Paavonen, Unnop Jaisamrarn, et al.
International Journal of Cancer|January 3, 2014
Time trends of human papillomavirus types in invasive cervical cancer, from 1940 to 2007Laia Alemany, Silvia de Sanjosé, Sara Tous, et al.
Vaccine|November 16, 2013
Comprehensive control of human papillomavirus infections and related diseasesF Xavier Bosch, Thomas R Broker, David Forman, et al.
Pageof 69